Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation

Executive Summary

Sanofi-Aventis' revised R&D structure will include the push down to smaller, more independent structures that has characterized other big pharma companies' efforts to improve their R&D activity
Advertisement

Related Content

Life Without Plavix: Sanofi Highlights Next Generation Drugs
Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
Seen And Heard At BIO – From The IN VIVO Blog
With Streamlined Pipeline, Next Steps For Sanofi R&D Include Full Reorg
With Streamlined Pipeline, Next Steps For Sanofi R&D Include Full Reorg
GSK Tries to Mimic Real-World Biotech
GSK Tries to Mimic Real-World Biotech
GSK’s Viehbacher Charged To “Adapt” Sanofi-Aventis To New Realities

Topics

Advertisement
UsernamePublicRestriction

Register

PS051248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel